2 C
New York
Wednesday, February 1, 2023

Sutro Biopharma Inc. (NASDAQ: STRO): Is It A Buying Opportunity Again?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Sutro Biopharma Inc. (STRO) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $7.54. The Sutro Biopharma Inc. has recorded 39,278 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Stocks Info

STRO belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $7.54 and fluctuated between $7.67 as its day high and $7.48 as its day low. The current market capitalization of Sutro Biopharma Inc. is $407.76M. A total of 0.57 million shares were traded on the day, compared to an average of 581.62K shares.

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, STRO has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 24 BUYs and 17 SELLs from insiders. Insiders purchased 170,277 shares during that period but sold 53,567.

In the most recent transaction, NEWELL WILLIAM J bought 10,000 shares of STRO for 7.75 per share on Mar 14. After the transaction, the CEO now owns 116,525 company shares.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for STRO in the last 3 months, the mean price target is $22.13 with high estimates of $33.00 and low estimates of $15.00. In terms of 52-week highs and lows, STRO has a high of $10.98 and a low of $3.33.

As of this writing, STRO has an earnings estimate of -$0.74 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.65 per share and a lower estimate of -$0.93. The company reported an EPS of -$0.84 in the last quarter, which was -10.50% lower than expectations of -$0.76.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for STRO is Overweight with a score of 5.00. A total of 9 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles